Fucoidan elevates MicroRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells

Ming De Yan, Chih Jung Yao, Jyh Ming Chow, Chia Lun Chang, Pai An Hwang, Shuang En Chuang, Jacqueline Whang-Peng, Gi Ming Lai

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Accumulating evidence has revealed that fucoidan exhibits anti-tumor activities by arresting cell cycle and inducing apoptosis in many types of cancer cells including hepatocellular carcinoma (HCC). Exploring its effect on microRNA expression, we found that fucoidan markedly upregulated miR-29b of human HCC cells. The induction of miR-29b was accompanied with suppression of its downstream target DNMT3B in a dose-dependent manner. The reduction of luciferase activity of DNMT3B 3′-UTR reporter by fucoidan was as markedly as that by miR-29b mimic, indicating that fucoidan induced miR-29b to suppress DNMT3B. Accordingly, the mRNA and protein levels of MTSS1 (metastasis suppressor 1), a target silenced by DNMT3B, were increased after fucoidan treatment. Furthermore, fucoidan also down-regulated TGF-β receptor and Smad signaling of HCC cells. All these effects leaded to the inhibition of EMT (increased E-cadherin and decreased N-cadherin) and prevention of extracellular matrix degradation (increased TIMP-1 and decreased MMP2, 9), by which the invasion activity of HCC cells was diminished. Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC.

Original languageEnglish
Pages (from-to)6099-6116
Number of pages18
JournalMarine Drugs
Volume13
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

MicroRNAs
Hepatocellular Carcinoma
Neoplasm Metastasis
Cadherins
Tumor Suppressor Proteins
Tissue Inhibitor of Metalloproteinase-1
fucoidan
3' Untranslated Regions
Luciferases
Extracellular Matrix
Neoplasms
Cell Cycle
Apoptosis
Messenger RNA

Keywords

  • DNMT3B
  • EMT
  • Fucoidan
  • Hepatocellular carcinoma
  • MiR-29b
  • MTSS1

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Fucoidan elevates MicroRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells. / Yan, Ming De; Yao, Chih Jung; Chow, Jyh Ming; Chang, Chia Lun; Hwang, Pai An; Chuang, Shuang En; Whang-Peng, Jacqueline; Lai, Gi Ming.

In: Marine Drugs, Vol. 13, No. 10, 01.10.2015, p. 6099-6116.

Research output: Contribution to journalArticle

@article{13fa9d18a1104d7985898497d64983ff,
title = "Fucoidan elevates MicroRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells",
abstract = "Accumulating evidence has revealed that fucoidan exhibits anti-tumor activities by arresting cell cycle and inducing apoptosis in many types of cancer cells including hepatocellular carcinoma (HCC). Exploring its effect on microRNA expression, we found that fucoidan markedly upregulated miR-29b of human HCC cells. The induction of miR-29b was accompanied with suppression of its downstream target DNMT3B in a dose-dependent manner. The reduction of luciferase activity of DNMT3B 3′-UTR reporter by fucoidan was as markedly as that by miR-29b mimic, indicating that fucoidan induced miR-29b to suppress DNMT3B. Accordingly, the mRNA and protein levels of MTSS1 (metastasis suppressor 1), a target silenced by DNMT3B, were increased after fucoidan treatment. Furthermore, fucoidan also down-regulated TGF-β receptor and Smad signaling of HCC cells. All these effects leaded to the inhibition of EMT (increased E-cadherin and decreased N-cadherin) and prevention of extracellular matrix degradation (increased TIMP-1 and decreased MMP2, 9), by which the invasion activity of HCC cells was diminished. Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC.",
keywords = "DNMT3B, EMT, Fucoidan, Hepatocellular carcinoma, MiR-29b, MTSS1",
author = "Yan, {Ming De} and Yao, {Chih Jung} and Chow, {Jyh Ming} and Chang, {Chia Lun} and Hwang, {Pai An} and Chuang, {Shuang En} and Jacqueline Whang-Peng and Lai, {Gi Ming}",
year = "2015",
month = "10",
day = "1",
doi = "10.3390/md13106099",
language = "English",
volume = "13",
pages = "6099--6116",
journal = "Marine Drugs",
issn = "1660-3397",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - Fucoidan elevates MicroRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells

AU - Yan, Ming De

AU - Yao, Chih Jung

AU - Chow, Jyh Ming

AU - Chang, Chia Lun

AU - Hwang, Pai An

AU - Chuang, Shuang En

AU - Whang-Peng, Jacqueline

AU - Lai, Gi Ming

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Accumulating evidence has revealed that fucoidan exhibits anti-tumor activities by arresting cell cycle and inducing apoptosis in many types of cancer cells including hepatocellular carcinoma (HCC). Exploring its effect on microRNA expression, we found that fucoidan markedly upregulated miR-29b of human HCC cells. The induction of miR-29b was accompanied with suppression of its downstream target DNMT3B in a dose-dependent manner. The reduction of luciferase activity of DNMT3B 3′-UTR reporter by fucoidan was as markedly as that by miR-29b mimic, indicating that fucoidan induced miR-29b to suppress DNMT3B. Accordingly, the mRNA and protein levels of MTSS1 (metastasis suppressor 1), a target silenced by DNMT3B, were increased after fucoidan treatment. Furthermore, fucoidan also down-regulated TGF-β receptor and Smad signaling of HCC cells. All these effects leaded to the inhibition of EMT (increased E-cadherin and decreased N-cadherin) and prevention of extracellular matrix degradation (increased TIMP-1 and decreased MMP2, 9), by which the invasion activity of HCC cells was diminished. Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC.

AB - Accumulating evidence has revealed that fucoidan exhibits anti-tumor activities by arresting cell cycle and inducing apoptosis in many types of cancer cells including hepatocellular carcinoma (HCC). Exploring its effect on microRNA expression, we found that fucoidan markedly upregulated miR-29b of human HCC cells. The induction of miR-29b was accompanied with suppression of its downstream target DNMT3B in a dose-dependent manner. The reduction of luciferase activity of DNMT3B 3′-UTR reporter by fucoidan was as markedly as that by miR-29b mimic, indicating that fucoidan induced miR-29b to suppress DNMT3B. Accordingly, the mRNA and protein levels of MTSS1 (metastasis suppressor 1), a target silenced by DNMT3B, were increased after fucoidan treatment. Furthermore, fucoidan also down-regulated TGF-β receptor and Smad signaling of HCC cells. All these effects leaded to the inhibition of EMT (increased E-cadherin and decreased N-cadherin) and prevention of extracellular matrix degradation (increased TIMP-1 and decreased MMP2, 9), by which the invasion activity of HCC cells was diminished. Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC.

KW - DNMT3B

KW - EMT

KW - Fucoidan

KW - Hepatocellular carcinoma

KW - MiR-29b

KW - MTSS1

UR - http://www.scopus.com/inward/record.url?scp=84945932924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945932924&partnerID=8YFLogxK

U2 - 10.3390/md13106099

DO - 10.3390/md13106099

M3 - Article

C2 - 26404322

AN - SCOPUS:84945932924

VL - 13

SP - 6099

EP - 6116

JO - Marine Drugs

JF - Marine Drugs

SN - 1660-3397

IS - 10

ER -